Nov 29, 2023 7:59am EST Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Nov 09, 2023 7:59am EST Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
Sep 07, 2023 4:14pm EDT Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Aug 01, 2023 7:59am EDT Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
Jul 20, 2023 8:43am EDT Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
Jul 20, 2023 8:40am EDT Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
Jun 30, 2023 9:28am EDT Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
Jun 06, 2023 4:30pm EDT Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.
